Systemic therapy for bladder cancer is costly and should be weighed against the clinical outcomes likely to be achieved.
Through an appreciation of heuristics, we can better understand the factors that influence the decision-making processes of different stakeholders and adjust our approach to delivering value-based care to our patients.
This retrospective, longitudinal study was conducted to identify drivers of chronic kidney disease stage progression and associated health care costs.
Express Scripts recently announced the purchase of eviCore, a leading medical benefits management firm, for $3.6 billion. The merger has the potential to be the first comprehensive care management offering.
The potential impact of CAR-T therapies should not be underestimated, nor should their complexity, which is why a broader understanding of stakeholder knowledge and perception may be critical to their adoption and use.
This paper explores the growing trend of clinical pathways for symptom management—including how they can be applied across cancer care and the positive downstream effects of pathways for symptom control—by examining the implementation of symptom management clinical pathways at one treatment center.
The Impact of Decreasing Variability in Surgical Care Through a Structured Multi-Disciplinary Thoracic Oncology Program
Post-TOP lobectomy is associated with increased clinical staging, greater utilization of mediastinoscopy and bronchoscopy, performance of minimally invasive resection, greater number of lymph nodes procured, and decreased length of stay.
Rationale for the Development of Clinical Pathways and an Overview of the Clinical Pathways Office at the Seattle Cancer Care Alliance
This paper examines the establishment of the Seattle Cancer Care Alliance Clinical Pathways Office, as well as the goals of clinical pathway development from the standpoint of a regional hospital system.
The authors review information to guide the appropriate management of older adults with multiple myeloma and discuss issues that may arise from the multidisciplinary management of this patient population.
Pharmaceutical Manufacturer Responses to Health Care Professional and Clinical Pathway Developer Requests for Medical Information
The purpose of this article is to describe the role of the MIS and MSL in responding to requests from HCPs and clinical pathways developers for up-to-date, evidence-based product information to enable them to make informed decisions about patient care.